IT-29 * IMMUNE CHECKPOINT BLOCKADE FOR GLIOBLASTOMA: PRECLINICAL ACTIVITY OF SINGLE AGENT AND COMBINATORIAL THERAPY
David A. Reardon(Dana-Farber Cancer Institute), Gordon J. Freeman(Dana-Farber Cancer Institute), Nancy E. Kohl(United States Military Academy), Stephen Hodi(Dana-Farber Cancer Institute), Jun Zhou(Dana-Farber Cancer Institute), Lei Qin(Dana-Farber Brigham Cancer Center), Scott J. Rodig(Brigham and Women's Hospital), Keith T. Jones(University of Sussex), Arnaud Sauer(Hôpitaux Universitaires de Strasbourg), Xiaoyun Liao(Bristol-Myers Squibb (Germany)), Keith L. Ligon(Brigham and Women's Hospital), Prafulla C. Gokhale(Harvard University), Glenn Dranoff(Dana-Farber Cancer Institute)
Cited by 4
Related Papers
Long-Term Colorectal-Cancer Incidence and Mortality after Lower Endoscopy
|New England Journal of Medicine|2013|1.5k
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
|Nature|2018|1.5k
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
|Nature Communications|2015|1.2k